May 15, 2019—Developed in partnership with and endorsed by the European Heart Rhythm Association, the Asia Pacific Heart Rhythm Society, and the Latin American Heart Rhythm Society, the focused update (centered on Appendix B) relates to the updated manufacturer-specific programming settings/choices based on a compilation of clinical expertise and clinical trial data as reported in the 2015 HRS/EHRA/APHRS/SOLAECE Expert Consensus Statement on Optimal Implantable Cardioverter-Defibrillator Programming and Testing of which Appendix B is a part.
The recommended settings/choices represent a diligent effort on the part of the writing committee to translate the consensus statement recommendations to device settings/choices for the specified clinical issues/ICD therapies where the writing committee considered that there was sufficient consensus and supporting data to make recommendations intended to improve the safety, morbidity, and mortality profile of patients with these clinical issues/ICD therapies.
Topic
- Clinical EP
- Clinical Topics
- Device Therapy
Resource Type
- Clinical Documents
Related Resources

Clinical Documents
18F-FDG PET/CT and Radiolabeled Leukocyte SPECT/CT Imaging for the Evaluation of Cardiovascular Infection in the Multimodality Context
March 11, 2024

Clinical Documents
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Patients With Atrial Fibrillation
November 30, 2023

Clinical Documents
2003 NASPE Training Requirements for Cardiac Implantable Electronic Devices: Selection, Implantation, and Follow-Up
July 1, 2023